Nuvaxovid

(COVID-19 vaccine (recombinant protein, adjuvanted))

Nuvaxovid

Drug updated on 10/23/2023

Dosage FormInjection (intramuscular; 5mcg/0.5 mL)
Drug ClassVaccines
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.